Researchers at Children's Hospital of Philadelphia (CHOP) announced encouraging results from the first ever gene therapy trial for Danon disease (DD), a rare, X-linked heart condition caused by a ...

Rocket’s RP-A501 for Danon disease has potential to be a $1B commercial opportunity, the analyst tells investors in a research note. The firm thinks an accelerated approval pathway may be ...

Yun Zhong, an analyst from Wedbush, has initiated a new Buy rating on Rocket Pharmaceuticals (RCKT).Don't Miss Our New Year's Offers:Discover ...

Results came from a phase 1 trial of RP-A501 for treatment of Danon Disease and sent shares up 75% on the Nasdaq to more than $56, a five-year high. The surging stock price indicates the market's ...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stock has hit a 52-week low, dropping to $10.11, as the company faces a ...

Israel’s Ambassador to the United Nations, Danny Danon, commented on Saturday on the Health Ministry special report, outlining the physical and mental conditions of the hostages who were ...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. Rocket Pharmaceuticals, Inc ...

The company's key programs include treatments for Danon disease, PKP2-ACM arrhythmogenic cardiomyopathy, LAD-I deficiency, Fanconi anemia, and PKD deficiency. The company's lead candidate ...

Particularly, the lead program RP-A501 for Danon disease shows a strong potential for market success, given its high probability of success and a substantial market opportunity. The agreement with ...